J.W. Cole Advisors Inc. Reduces Stock Position in Boston Scientific Corporation $BSX

J.W. Cole Advisors Inc. cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 61.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,566 shares of the medical equipment provider’s stock after selling 13,668 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Boston Scientific were worth $836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Steph & Co. bought a new stake in Boston Scientific during the 3rd quarter valued at approximately $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific during the 3rd quarter valued at approximately $25,000. United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth approximately $30,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. UBS Group reduced their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday. Barclays lowered their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. National Bankshares set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Finally, Citigroup decreased their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $109.43.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $74.20 on Tuesday. The firm has a market cap of $110.00 billion, a P/E ratio of 38.25, a PEG ratio of 1.60 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $74.07 and a twelve month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a 50 day moving average of $92.85 and a 200 day moving average of $98.47.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.